|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Juniper Pharmaceuticals (JNP) delivered earnings and revenue surprises of -450.00% and -6.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Boston-based company said it had a loss of 14 cents per share. The pharmaceutical company posted revenue of $15.3 million in the period. Juniper Pharmaceuticals shares have more than doubled since ...
Signs Agreement to be Acquired by Catalent, Inc. CRINONE® Revenues Increased 12% and Juniper Pharma Services (JPS) Revenues Increased 41% for the Six-months Ended June 30, 2018 vs. Prior Year BOSTON , ...
Under the terms of the transaction, Juniper shareholders will receive only $11.50 in cash for each share of Juniper stock they own. The investigation concerns whether the Board of Juniper breached their fiduciary duties to shareholders and whether Catalent is underpaying for the Company.
NEW YORK , July 10, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
NEW YORK , July 5, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Juniper Pharmaceuticals, Inc. ("JNP" ...
Juniper Pharmaceuticals, Inc. (JNP) inks a deal with Catalent, Inc. Per the deal, Catalent will acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.
NEW YORK, NY / ACCESSWIRE / July 4, 2018 / Health stocks Anavex Life Sciences Corp. and Juniper Pharmaceuticals were both exploding in Tuesday trading on positive developments. Anavex announced it has ...
SAN DIEGO , July 3, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Juniper Pharmaceuticals, Inc. ("Juniper") ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 2) Acer Therapeutics Inc (NASDAQ: ACER ) Arrowhead Pharmaceuticals ...
U.S. drug contract manufacturer Catalent Inc said on Tuesday it will buy Juniper Pharmaceuticals Inc for $11.50 per share in cash. The offer price represents a premium of about 32 percent to Juniper Pharmaceuticals' closing price of $8.70 on Monday and values the company at about $127.7 million, according to Thomson Reuters calculations. Catalent has a market value of about $5.58 billion, according to Thomson Reuters data.
BOSTON, July 3, 2018 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fee-for-service contract development and manufacturing organization (CDMO) Juniper Pharma Services (JPS), today announced it has entered into a definitive agreement with Catalent, Inc. for Catalent to acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash. The transaction represents a total equity value of approximately $139.6 million on a fully-diluted basis, and a premium of 59.7% to Juniper's unaffected share price on January 30, 2018, the last trading day prior to the date on which Juniper announced its intention to explore strategic alternatives. "This transaction, which has been approved unanimously by the Juniper Board of Directors following the recommendation of a special committee of independent directors, is the culmination of a diligent and extensive process to pursue strategic alternatives in order to maximize shareholder value," said Alicia Secor, Juniper's President and CEO.